Prospective, randomized, multicenter, open label phase II study to access efficacy and safety of Lucentis® monotherapy (ranibizumab 0.5 mg intravitreal injections) compared with Lucentis® plus panretinal photocoagulation (PRP) and PRP (monotherapy) in the treatment of patients with high risk proliferative diabetic retinopathy

Coordinator

José Cunha-Vaz

Start

February 2010

End

July 2011

Centres and/or Units

4C - Coimbra Coordinating Centre for Clinical Research

Research area

Proliferative Diabetic Retinopathy

Projects by department: